

P0023

Poster Session I

News from the fungal frontier

SYNERGISTIC EFFECTS OF DIPHENYL DISELENIDE AND AMPHOTERICIN B IN TRICHOSPORON ASAHII ISOLATES

D. Alves Nunes Mario¹, T. Felli KubiÁa¹, P. Orlandi Barth¹, E. Silva de Loreto¹, C. Nogueira¹, L. Bedin Denardi¹, S. Hartz Alves¹

¹Microbiology and Parasitology, Universidade Federal de Santa Maria, Santa Maria/ Rio Grande do sul, Brazil

Disseminated infections caused by *Trichosporon asahii* are difficult to resolve. Combination regimens with synergistic drugs could provide additional options for treating trichosporonosis.

OBJECTIVES: In this context, the aim of this study was to evaluate the *in vitro* activity of diphenyl diselenide [(PhSe)₂] alone and in combination with amphotericin B against *Trichosporon asahii* clinical isolates.

METHODS: Susceptibility tests were performed according to the CLSI protocol M27-A3 microdilution technique and the interaction between diphenyl diselenide [(PhSe)₂] and amphotericin B against 10 *Trichosporon asahii* clinical isolates was evaluated using the microdilution checkerboard method. The concentrations of diphenyl diselenide [(PhSe)₂] ranged from 0.5 µg/mL to 64 µg/mL, and the concentrations of the amphotericin B ranged from 0.03 µg/mL to 4 µg/mL. The fractional inhibitory concentration (FIC) was calculated for each agent by dividing the minimal inhibitory concentration (MIC) of each drug in combination by the MIC of the drug alone. The FIC values were then totaled to determine the fractional inhibitory concentration index (FICI) that resulted from the drug combinations. Synergism was defined as an FICI ≤ 0.5, indifference was defined as 0.5 < FICI ≤ 4, and antagonism was defined as FICI > 4.

RESULTS: The results of the *in vitro* susceptibility test, FICI and the resulting drug interactions against the *Trichosporon asahii* clinical isolates are described in Table 1. MICs ranged from 8 to 64 for (PhSe)₂ and 1 to 4 for amphotericin B. When *T. asahii* isolates were tested for the (PhSe)₂ + amphotericin B synergistic interactions were observed in 100% of the isolates, whereas no antagonistic or indifferent interactions were observed.

Clinical isolates	MIC (µg/mL)		MIC (µg/mL) combination		
	AmB	(PhSe) ₂	AmB / (PhSe) ₂	FICI	Interaction
Ta 1	1	8	0.25/0.5	0.3125	Synergism
Ta 2	1	8	0.25/0.5	0.3125	Synergism
Ta 3	1	8	0.25/0.5	0.3125	Synergism
Ta 4	1	8	0.125/0.5	0.1875	Synergism
Ta 5	4	64	0.031/8	0.0703	Synergism
Ta 6	2	64	0.25/0.5	0.1328	Synergism
Ta 7	1	8	0.25/0.5	0.3125	Synergism
Ta 8	2	8	0.25/0.5	0.1875	Synergism
Ta 9	1	32	0.25/0.5	0.265	Synergism
Ta 10	4	64	0.031/8	0.0703	synergism

CONCLUSION: In conclusion, we reported that (PhSe)₂ inhibited the *in vitro* growth of *Trichosporon asahii* isolates, and we provided a new approach to *Trichosporon asahii* susceptibility studies once the association of (PhSe)₂ with AmB presents a synergistic potential. New experimental *in vivo* protocols are needed and will promote a better understanding of (PhSe)₂ antimicrobial activity and its use as an adjuvant therapy with antifungal agents.